1. Home
  2. OPEN vs CINGW Comparison

OPEN vs CINGW Comparison

Compare OPEN & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPEN
  • CINGW
  • Stock Information
  • Founded
  • OPEN 2014
  • CINGW N/A
  • Country
  • OPEN United States
  • CINGW United States
  • Employees
  • OPEN N/A
  • CINGW 13
  • Industry
  • OPEN Real Estate
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • OPEN Finance
  • CINGW Health Care
  • Exchange
  • OPEN Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • OPEN N/A
  • CINGW N/A
  • IPO Year
  • OPEN N/A
  • CINGW 2021
  • Fundamental
  • Price
  • OPEN $0.95
  • CINGW $0.04
  • Analyst Decision
  • OPEN Hold
  • CINGW
  • Analyst Count
  • OPEN 5
  • CINGW 0
  • Target Price
  • OPEN $1.70
  • CINGW N/A
  • AVG Volume (30 Days)
  • OPEN 37.6M
  • CINGW N/A
  • Earning Date
  • OPEN 05-06-2025
  • CINGW N/A
  • Dividend Yield
  • OPEN N/A
  • CINGW N/A
  • EPS Growth
  • OPEN N/A
  • CINGW N/A
  • EPS
  • OPEN N/A
  • CINGW N/A
  • Revenue
  • OPEN $5,153,000,000.00
  • CINGW N/A
  • Revenue This Year
  • OPEN $3.84
  • CINGW N/A
  • Revenue Next Year
  • OPEN $21.51
  • CINGW N/A
  • P/E Ratio
  • OPEN N/A
  • CINGW N/A
  • Revenue Growth
  • OPEN N/A
  • CINGW N/A
  • 52 Week Low
  • OPEN $0.85
  • CINGW N/A
  • 52 Week High
  • OPEN $3.09
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • OPEN 39.87
  • CINGW N/A
  • Support Level
  • OPEN $0.90
  • CINGW N/A
  • Resistance Level
  • OPEN $1.04
  • CINGW N/A
  • Average True Range (ATR)
  • OPEN 0.11
  • CINGW 0.00
  • MACD
  • OPEN -0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • OPEN 39.53
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: